These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

704 related articles for article (PubMed ID: 20345506)

  • 41. Detection of EBV DNA in the cord blood donor for a patient developing Epstein-Barr virus-associated lymphoproliferative disorder following mismatched unrelated umbilical cord blood transplantation.
    Haut PR; Kovarik P; Shaw PH; Walterhouse D; Jenson HB; Kletzel M
    Bone Marrow Transplant; 2001 Apr; 27(7):761-5. PubMed ID: 11360119
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Heterogeneity in clinical course of EBV-associated lymphoproliferative disorder after allogeneic stem cell transplantation.
    Meyer SC; Medinger M; Halter JP; Baldomero H; Hirsch HH; Tzankov A; Dirnhofer S; Passweg JR; Tichelli A
    Hematology; 2014 Jul; 19(5):280-5. PubMed ID: 24074746
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation.
    Orjuela MA; Alobeid B; Liu X; Siebert AL; Kott ER; Addonizio LJ; Morris E; Garvin JH; Lobritto SJ; Cairo MS
    Br J Haematol; 2011 Mar; 152(6):733-42. PubMed ID: 21275950
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The efficacy and safety of donor lymphocyte infusion to treat Epstein-Barr virus associated lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation].
    Xu LP; Liu DH; Liu KY; Chen H; Han W; Wang Y; Wang J; Shi HX; Huang XJ
    Zhonghua Nei Ke Za Zhi; 2010 Nov; 49(11):955-8. PubMed ID: 21211211
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients.
    Zangwill SD; Hsu DT; Kichuk MR; Garvin JH; Stolar CJ; Haddad J; Stylianos S; Michler RE; Chadburn A; Knowles DM; Addonizio LJ
    J Heart Lung Transplant; 1998 Dec; 17(12):1161-6. PubMed ID: 9883755
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation.
    Ahmad I; Cau NV; Kwan J; Maaroufi Y; Meuleman N; Aoun M; Lewalle P; Martiat P; Crokaert F; Bron D
    Transplantation; 2009 Apr; 87(8):1240-5. PubMed ID: 19384173
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Late-onset posttransplant Epstein-Barr virusrelated lymphoproliferative disease after cord blood transplantation for chronic active Epstein Barr virus infection: A case report.
    Yamamoto M; Shindo M; Funayama T; Sumi C; Saito T; Toki Y; Hatayama M; Imadome KI; Mizukami Y; Okumura T
    Medicine (Baltimore); 2022 Mar; 101(12):e29055. PubMed ID: 35357349
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
    Oertel S; Trappe RU; Zeidler K; Babel N; Reinke P; Hummel M; Jonas S; Papp-Vary M; Subklewe M; Dörken B; Riess H; Gärtner B
    Ann Hematol; 2006 Jul; 85(7):478-84. PubMed ID: 16586109
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Latest update on immunotherapy of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease].
    Hao QF; Sheng GY; Luan Z
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Sep; 15(9):795-9. PubMed ID: 24034931
    [TBL] [Abstract][Full Text] [Related]  

  • 50. EBV-associated B- and T-cell posttransplant lymphoproliferative disorders following primary EBV infection in a kidney transplant recipient.
    Yin CC; Medeiros LJ; Abruzzo LV; Jones D; Farhood AI; Thomazy VA
    Am J Clin Pathol; 2005 Feb; 123(2):222-8. PubMed ID: 15842046
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discrimination of Epstein-Barr virus-related posttransplant lymphoproliferations from acute rejection in lung allograft recipients.
    Rosendale B; Yousem SA
    Arch Pathol Lab Med; 1995 May; 119(5):418-23. PubMed ID: 7748068
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation.
    Lindsay J; Yong MK; Greenwood M; Kong DCM; Chen SCA; Rawlinson W; Slavin M
    Rev Med Virol; 2020 Jul; 30(4):e2108. PubMed ID: 32301566
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation.
    Rea D; Fourcade C; Leblond V; Rowe M; Joab I; Edelman L; Bitker MO; Gandjbakhch I; Suberbielle C; Farcet JP
    Transplantation; 1994 Aug; 58(3):317-24. PubMed ID: 8053055
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
    Chen DB; Wang Y; Song QJ; Shen DH
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation.
    Carpenter B; Haque T; Dimopoulou M; Atkinson C; Roughton M; Grace S; Denovan S; Fielding A; Kottaridis PD; Griffiths P; Mackinnon S; Emery V; Chakraverty R
    Transplantation; 2010 Sep; 90(5):564-70. PubMed ID: 20555307
    [TBL] [Abstract][Full Text] [Related]  

  • 56. EBV lymphoproliferative disease of host origin after haploidentical stem cell transplantation.
    Kasow KA; Leung W; Horwitz EM; Woodard P; Handgretinger R; Hale GA
    Pediatr Blood Cancer; 2007 Nov; 49(6):869-72. PubMed ID: 16421900
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab.
    Patriarca F; Medeot M; Isola M; Battista ML; Sperotto A; Pipan C; Toffoletti E; Dozzo M; Michelutti A; Gregoraci G; Geromin A; Cerno M; Savignano C; Rinaldi C; Barbone F; Fanin R
    Transpl Infect Dis; 2013 Jun; 15(3):259-67. PubMed ID: 23405972
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
    Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F
    Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Associations of serum EBV DNA and gammopathy with post-transplant lymphoproliferative disease.
    Rosselet A; Vu DH; Meylan P; Chaubert AS; Schapira M; Pascual M; Aubert V; Tissot JD; Duchosal MA
    Clin Transplant; 2009; 23(1):74-82. PubMed ID: 19200218
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The emergence of CD20-/CD19- tumor cells after rituximab therapy for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder complicated with hemophagocytic lymphohistiocytosis.
    Yamamoto N; Nishimura N; Takeuchi M; Ito T; Yokozaki H; Hirase S; Kubokawa I; Mori T; Yanai T; Hayakawa A; Takeshima Y; Nishio H; Matsuo M; Imadome K; Iijima K
    Eur J Pediatr; 2014 Dec; 173(12):1615-8. PubMed ID: 24169729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.